MedPath

Efficacy of Omega-3 in the treatment of Schizophrenia

Phase 1
Conditions
Schizophrenia.
The Schizophrenic Disorders Are Characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted.
Registration Number
IRCT201202117373N2
Lead Sponsor
Arak University Of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

age range 15-55years ,diagnosis of schizophrenia according to DSM4-TR criteria and clinical interview by psychiatrist ,informed written consent letter ,a score of at least 60 in PANSS( Positive and Negative Syndrome Scale).
Exclusion criteria :Pregnancy ,lactation, substance abuse ,sever physical disease,contraindication of Omega-3

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PANSS. Timepoint: Before Intervention,4th Week,8th Week. Method of measurement: Physical Exam And Clinical Intrview.
Secondary Outcome Measures
NameTimeMethod
Extra Pyramidal Side Effects. Timepoint: Before Intervention And Once Every 4 Weeks. Method of measurement: Physical Examination And Clinical Interview.
© Copyright 2025. All Rights Reserved by MedPath